Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin

2001 ◽  
Vol 28 (2) ◽  
pp. 198-202 ◽  
Author(s):  
Bart de Keizer ◽  
Hans P. F. Koppeschaar ◽  
Pierre M. J. Zelissen ◽  
Cees J. M. Lips ◽  
Peter P. van Rijk ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Serum Thyroglobulin ◽  
Iodine 131 ◽  
Therapeutic Doses ◽  
Detectable Serum

scholarly journals Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH

2001 ◽  
pp. 5-11 ◽  
Author(s):  
F Lippi ◽  
M Capezzone ◽  
F Angelini ◽  
D Taddei ◽  
E Molinaro ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Advanced Disease ◽  
Thyroid Stimulating Hormone ◽  
Whole Body ◽  
Suppressive Therapy ◽  
Serum Thyroglobulin ◽  
Body Scanning ◽  
Iodine 131 ◽  
Post Therapy

OBJECTIVE: This study tested the hypothesis that administration of human recombinant thyroid-stimulating hormone (rhTSH: Thyrogen, thyrotropin alpha) could promote iodine-131 ((131)I) uptake in the therapy for metastatic or locally invasive differentiated thyroid cancer (DTC), obviating L-thyroxine suppressive therapy (L-T4) withdrawal and hypothyroidism in patients with advanced disease. METHODS: Twelve totally (or almost completely) thyroidectomized adults, nine of whom had received earlier therapy after L-T4 withdrawal, underwent (131)I treatment while euthyroid on L-T4, after rhTSH administration. Nine underwent diagnostic whole-body scanning (WBS) after two consecutive daily i.m. injections (0.9 mg) of rhTSH. They then received an identical second course of rhTSH to promote therapeutic (131)I uptake. Post-therapy WBS was performed one week later. Three patients received only rhTSH (131)I therapy. RESULTS: Administration of rhTSH promoted (131)I uptake in all patients, as demonstrated by post-therapy WBS. Administration of rhTSH also promoted a significant increase in serum thyroglobulin (Tg) concentrations. According to the most recent measurements, 3-12 months after therapy, serum Tg levels fell in four, and stabilized in two out of eleven patients. Upon additional rhTSH-WBS 8 months post-study, a reduction in one metastatic site was noted in one patient. The rhTSH was well tolerated, with mild, transient fever and/or nausea occurring in only a minority of patients. Individuals with bone metastases experienced degrees of peritumoral pain and swelling that were similar (though more short-lived) to those seen in the same or other patients after L-T4 withdrawal. CONCLUSIONS: Administration of rhTSH is a safe, successful tool for inducing (131)I uptake in local and metastatic DTC lesions, and avoids L-T4 withdrawal, preserving metabolic homeostasis and preventing the debilitating effects of hypothyroidism.

Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations

1993 ◽  
Vol 20 (3) ◽  
Author(s):  
Dario Casara ◽  
Domenico Rubello ◽  
Giorgio Saladini ◽  
Andrea Piotto ◽  
MariaRosa Peiizzo ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Potential Risks ◽  
Iodine 131 ◽  
Therapeutic Doses

Pregnancy After High Therapeutic Doses of Iodine-131 in Differentiated Thyroid Cancer

1993 ◽  
Vol 48 (10) ◽  
pp. 652-653
Author(s):  
Dario Casara ◽  
Domenieo Rubello ◽  
Giorgio Saladini ◽  
Andrea Piotto ◽  
Maria Rosa Pelizzo ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Iodine 131 ◽  
Therapeutic Doses

The role of preoperative serum thyroglobulin values in the diagnosis of differentiated thyroid cancer

2017 ◽  
Author(s):  
Blertina Dyrmishi ◽  
Taulant Olldashi ◽  
Ema Lumi ◽  
Entela Puca ◽  
Dorina Ylli ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Serum Thyroglobulin ◽  
Preoperative Serum
Sign in / Sign up

Export Citation Format

Share Document